Power of the two one-sided tests procedure in bioequivalence

  • Kem F. Phillips
Pharmacometrics

Abstract

The power of the two one-sided tests procedure for testing bioequivalence is derived from the bivariate noncentral tdistribution. Power curves are shown and their use in planning bioequivalence experiments discussed. Sample sizes computed in the usual manner from an analysis of variance are shown to be too small to assure a declaration of bioequivalence except under favorable conditions.

Key words

bioequivalence hypothesis testing power sample size 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bioequivalence Task Force. Report on recommendations from the bioequivalence hearing conducted by the Food and Drug Administration, September 29–October 1, 1986.Google Scholar
  2. 2.
    D. J. Schuirmann. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.J. Pharmacokin. Biopharm. 15:657–680 (1987).CrossRefGoogle Scholar
  3. 3.
    W. W. Hauck and S. Anderson. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials.J. Pharmacokin, Biopharm. 12:83–91 (1984).CrossRefGoogle Scholar
  4. 4.
    R. E. Odeh and D. B. Owen.Tables for Normal Tolerance Limits, Sampling Plans, and Screening, Marcel Dekker, New York, 1980.Google Scholar
  5. 5.
    D. B. Owen, A special case of a noncentralt-distribution.Biometrika 52:437–446 (1965).CrossRefGoogle Scholar
  6. 6.
    SAS.SAS User's Guide: Basics, Version 5, SAS Institute, Cary, NC, 1985.Google Scholar
  7. 7.
    W. J. Westlake. The design and analysis of comparative blood-level trials. In J. Swarbrick (ed.),Current Concepts in the Pharmaceutical Sciences, Dosage Form Design and Bioavailability, Lea & Febiger, Philadelphia, 1973, pp. 149–179.Google Scholar

Copyright information

© Plenum Publishing Corporation 1990

Authors and Affiliations

  • Kem F. Phillips
    • 1
  1. 1.Department of Clinical and Scientific AffairsPfizer PharmaceuticalsNew York

Personalised recommendations